Eton Pharmaceutcials
ETON
12 hedge funds and large institutions have $7.05M invested in Eton Pharmaceutcials in 2018 Q4 according to their latest regulatory filings, with 12 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
6.54% more ownership
Funds ownership: 0% → 6.54% (+6.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$3.21M |
| 2 |
AIC
AWM Investment Company
New York
|
+$2.61M |
| 3 |
AMH
Apollo Management Holdings
New York
|
+$552K |
| 4 |
DC
Diametric Capital
Boston,
Massachusetts
|
+$362K |
| 5 |
PCM
Prelude Capital Management
New York
|
+$155K |
Top Sellers
ETON Hedge Fund Activity: Q4 2018 in Review
12 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Eton Pharmaceutcials (ETON) for Q4 2018, worth a combined $7.05M.
Buyers outnumbered sellers: 12 funds opened new ETON positions and 0 closed out — a net gain of 12 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Opaleye Management, opening a new position worth an estimated $3.21M.
- 12 institutional investors held Eton Pharmaceutcials (ETON) as of Q4 2018, up from 0 in Q3 2018.
- Funds reported $7.05M of Eton Pharmaceutcials stock for Q4 2018.
- 12 funds opened new Eton Pharmaceutcials positions in Q4 2018 and 0 closed out, a net change of +12 holders.
- The largest Eton Pharmaceutcials buyer in Q4 2018 was Opaleye Management, an estimated $3.21M added.
Based on aggregated 13F filings for Q4 2018.